GALERA THERAPEUTICS, INC. (GRTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRTX Stock Price Chart Interactive Chart >
GRTX Price/Volume Stats
|Current price||$1.62||52-week high||$10.79|
|Prev. close||$1.74||52-week low||$1.15|
|Day high||$1.70||Avg. volume||436,875|
|50-day MA||$1.97||Dividend yield||N/A|
|200-day MA||$3.59||Market Cap||43.45M|
GALERA THERAPEUTICS, INC. (GRTX) Company Bio
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
Most Popular Stories View All
GRTX Latest News Stream
|Loading, please wait...|
GRTX Latest Social Stream
View Full GRTX Social Stream
Latest GRTX News From Around the Web
Below are the latest news stories about Galera Therapeutics Inc that investors may wish to consider to help them evaluate GRTX as an investment opportunity.
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022. A webcast of the presentation will be availab
Galera Therapeutics, Inc. (NASDAQ:GRTX) Director Linda West acquired 20,000 shares of the companys stock in a transaction dated Friday, December 17th. The shares were purchased at an average cost of $2.74 per share, for a total transaction of $54,800.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through 
Thinking about buying stock in Prelude Therapeutics, Miniso Group, Galera Therapeutics, Spruce Biosciences, or Purple Innovation?
NEW YORK , Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRLD, MNSO, GRTX, SPRB, and PRPL. Full story available on Benzinga.com
HC Wainwright upgraded shares of Galera Therapeutics (NASDAQ:GRTX) from a neutral rating to a buy rating in a research report report published on Wednesday morning, Price Targets.com reports. They currently have $10.00 price target on the stock. Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Galera Therapeutics 
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news. Among the regulatory decisions for the week, the Food and Drug Administration gave the green light to argenx SE''s (NASDAQ: ARGX ) efgartigimod for the treatment of generalized myasthenia gravis. AstraZeneca plc (NASDAQ: AZN ) and Amgen, Inc. (NASDAQ: AMGN ) announced an FDA nod for their Tezspire as a treatment option for severe asthma for those aged 12 years and older. Bristol-Myers Squibb Company ''s (NYSE: BMY ) Orencia was approved for the prophylactic treatment of acute graft-versus-host disease. Calliditas Therapeutics AB (publ) (NASDAQ: CALT ) scored an ...
GRTX Price Returns